Business ❯ Pharmaceuticals ❯ Acquisitions

Drug Development

Clinical Trials ALS Treatment Obesity Treatments Sleep Disorders Inflammatory Diseases Bispecific Antibodies Brelovitug Allergy Treatments

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

The Phase 1/2 asset targets PIK3CA‑mutant tumors to improve tolerability in HR+/HER2‑ breast cancer with closing expected in the first half of 2026.

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug